A Micro-Simulation Model of the Benefits and Costs of Prostate Cancer Screening and Treatment

Abstract

This idea development award developed a micro-simulation model of prostate cancer screening and treatment. As described in our initial proposal, we developed an detailed model of the natural history, screening, and treatment of prostate cancer organized around a Markov model that incorporated true stage and grade of tumor, misclassification of tumors that generates discrepancies between clinical and true stage, and other innovative features that had been neglected in prior models. We also extended the model to account for persistent heterogeneity that would not be adequately modeled by usual Markov models. We also did a detailed structured literature review to estimate key parameters of our model and developed new techniques to estimate the parameters of the natural history model by fitting it to aggregate and individual-level data from the SEER program. Our baseline analysis suggests that screening and treatment will increase life expectancy but decrease quality-adjusted life expectancy. Potential gains are largest in men ages SO-70 and when undiagnosed cancer creates substantial anxiety. We published a paper based on some initial analyses of treatment patterns, have a main cost-effectiveness manuscript in progress, and received ROl funding from the National Cancer Institute to further extend this work.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Jan 01, 2002
Accession Number
ADA406735

Entities

People

  • David O. Meltzer
  • Ibrahim Abdalla

Organizations

  • University of Chicago

Tags

DTIC Thesaurus Topics

  • Biomedical Research
  • Cancer Screening
  • Cost Effectiveness
  • Costs
  • Diseases And Disorders
  • Economics
  • Health Care
  • Health Services
  • Literature Surveys
  • Medical Personnel
  • Natural History
  • Neoplasms
  • Prostate Cancer
  • Public Health
  • Quality Of Life
  • Simulations
  • Therapy

Readers

  • Computational Modeling and Simulation
  • Oncology
  • Oncology and Biomarker-Based Cancer Detection.